Maioli E, Marchese A, Roveta S, Cagnacci S, Cavallini F, Cassanelli C, Gualco L, Debbia E A
Microbiology-DISCAT, University of Genova, Genova, Italy.
J Chemother. 2007 Apr;19(2):152-60. doi: 10.1179/joc.2007.19.2.152.
Some new features of the in vitro activity of ceftibuten, an oral third generation cephalosporin, have been studied in reference to respiratory and urinary tract pathogens included in its antibacterial spectrum. At 0.25XMIC (minimum inhibitory concentration) and 0.5XMIC levels, ceftibuten was able to affect the biofilm production in 2/3 of both Escherichia coli and Proteus mirabilis strains, and reduced the number of strains capable of adhering to epithelial cells by about 35% in comparison to the control. Surface hydrophobicity was also influenced by ceftibuten and the other drugs at 0.25-0.5XMIC. In general, no marked variation in the virulence traits of the pathogens studied were found by exposing bacteria to sub-MICs of ceftibuten. Plasmid loss (from 1.8 to 37.2%), and Flac transfer inhibition (about 30-50% reduction in the number of recombinants) were detected under the experimental conditions used. This study confirms the excellent antibacterial properties of ceftibuten by adding new information about the effects of this antibiotic against pathogens often involved in respiratory and urinary tract infections that may be treated with this compound, supporting the appropriate use of this cephalosporin.
就口服第三代头孢菌素头孢布烯对其抗菌谱内呼吸道和泌尿道病原体的体外活性的一些新特性进行了研究。在0.25倍最小抑菌浓度（MIC）和0.5倍MIC水平下，头孢布烯能够影响三分之二的大肠杆菌和奇异变形杆菌菌株的生物膜形成，并且与对照组相比，能够使能够黏附上皮细胞的菌株数量减少约35%。在0.25 - 0.5倍MIC时，头孢布烯和其他药物也会影响表面疏水性。总体而言，将细菌暴露于头孢布烯的亚MIC浓度下，未发现所研究病原体的毒力特性有明显变化。在所采用的实验条件下，检测到质粒丢失（从1.8%至37.2%）以及弗氏志贺菌转移抑制（重组体数量减少约30 - 50%）。本研究通过补充有关该抗生素对可能用该化合物治疗的呼吸道和泌尿道感染中常见病原体的作用的新信息，证实了头孢布烯优异的抗菌特性，支持了这种头孢菌素的合理使用。
